Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05055180
Other study ID # HFpEF-PHT 1.1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2018
Est. completion date December 30, 2021

Study information

Verified date September 2021
Source Heart Center Leipzig - University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In patients with heart failure and preserved ejection fraction (HFpEF) right ventricular (RV) systolic and diastolic dysfunction are prognostically and functionally relevant factors but have mechanistically been neglected so far. In the present study alterations of intrinsic RV (systolic and diastolic) function, as assessed by invasive pressure volume loops, are examined in relation to tissue alterations on myocardial level and to the degree of RV afterload (pulmonary hypertension). Study aim is to gain insights into mechanisms contributing to the development of RV dysfunction and potentially identify new therapeutic targets.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 30, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility HFpEF Inclusion Criteria: - Clinical signs of heart failure - Preserved Left ventricular (LV) Ejection Fraction (EF >= 50%) - Structural Heart Diseases on echocardiogram/ N terminal-pro-brain natriuretic peptide > 125ng/l - Elevated LV end-diastolic pressure at rest (>15mmHg) or during exertion (>=25mmHg) No Heart Failure Inclusion Criteria: - No signs of heart failure - Preserved Left ventricular (LV) Ejection Fraction (EF >= 50%) - Normal LV end-diastolic pressure at rest (=<15mmHg) and during exertion (<25mmHg) Exclusion Criteria: - Significant coronary artery stenosis at time of catheterization - Acute coronary syndrome or cerebral insult within 1 month of examination - more than moderate valvular diseases - pregnancy - contraindication to cardiac magnetic resonance imaging

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Invasive hemodynamics and myocardial biopsies
Invasive hemodynamic characterization (biventricular pressure volume loop assessment) and biventricular myocardial biopsies

Locations

Country Name City State
Germany Heart Center Leipzig at Leipzig University Leipzig Saxony

Sponsors (3)

Lead Sponsor Collaborator
Heart Center Leipzig - University Hospital University Hospital Muenster, University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Rommel KP, von Roeder M, Oberueck C, Latuscynski K, Besler C, Blazek S, Stiermaier T, Fengler K, Adams V, Sandri M, Linke A, Schuler G, Thiele H, Lurz P. Load-Independent Systolic and Diastolic Right Ventricular Function in Heart Failure With Preserved Ej — View Citation

von Roeder M, Kowallick JT, Rommel KP, Blazek S, Besler C, Fengler K, Lotz J, Hasenfuß G, Lücke C, Gutberlet M, Thiele H, Schuster A, Lurz P. Right atrial-right ventricular coupling in heart failure with preserved ejection fraction. Clin Res Cardiol. 2020 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Right ventricular systolic and diastolic function Assessed with pressure volume loops analysis Baseline
Primary Biventricular myocardial fibrosis Assessed with histopathology Baseline
Primary Phosphorylation of structural myocardial proteins Assessed on myocardial biopsy specimen Baseline
Secondary Functional capacity 6-Minute Walk Test / Spiroergometry Baseline
Secondary Myocardial fibrosis on cardiac magnetic resonance Baseline
See also
  Status Clinical Trial Phase
Suspended NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT06379152 - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Recruiting NCT05582044 - Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction N/A